ARTV Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. (ARTV) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 28% planned / 72% discretionary
Largest single sale: $690.4K.
Where they traded
Last open-market purchase: July 31, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Aslan Fred | Chief Executive Officer | Sell 10b5-1 | 23,429 | $10.92 | $255.7K | 1,449,765 −1.6% of holding | |
| Aslan Fred | Chief Executive Officer | Sell | 61,888 | $11.16 | $690.4K | 1,473,194 −4% of holding | |
| Horan Christopher | Chief Tech Operations Officer | Sell | 10,366 | $11.16 | $115.6K | 283,084 −3.5% of holding | |
| Bush Jennifer | COO, CLO, Compliance Officer | Sell | 8,391 | $11.16 | $93.6K | 329,529 −2.5% of holding | |
| Banerjee Subhashis | Chief Medical Officer | Sell | 1,100 | $11.16 | $12.3K | 140,947 −0.8% of holding | |
| Banerjee Subhashis | Chief Medical Officer | Sell 10b5-1 | 8,222 | $12.01 | $98.7K | 142,047 −5.5% of holding | |
| Banerjee Subhashis | Chief Medical Officer | Sell 10b5-1 | 429 | $12.00 | $5.1K | 144,963 −0.3% of holding | |
| Buy | 24,944 | $9.93 | $247.7K | 17,329,570 | |||
| Buy | 20,824 | $9.99 | $208.0K | 17,304,626 | |||
| Buy | 41,319 | $9.99 | $412.8K | 17,283,802 | |||
| Buy | 59,880 | $9.96 | $596.4K | 17,242,483 | |||
| Buy | 84,124 | $9.93 | $835.4K | 17,182,603 | |||
| Buy | 120,582 | $9.55 | $1.2M | 17,098,479 | |||
| Buy | 7,882 | $8.95 | $70.5K | 16,977,927 | |||
| Buy | 152,472 | $8.93 | $1.4M | 16,970,045 | |||
| 2 fills | Buy | 13,074 | $8.94 | $116.9K | 16,817,573 | ||
| Buy | 15,102 | $8.97 | $135.5K | 16,811,021 | |||
| Buy | 1,876 | $8.98 | $16.8K | 16,795,919 | |||
| Buy | 31,000 | $8.88 | $275.3K | 16,794,043 | |||
| Buy | 124,893 | $8.89 | $1.1M | 16,763,043 | |||
| Buy | 15,414 | $8.99 | $138.6K | 16,638,150 | |||
| Buy | 391,019 | $8.57 | $3.4M | 16,622,736 | |||
| Buy | 548,580 | $7.91 | $4.3M | 16,231,717 | |||
| Buy | 103 | $7.00 | $721 | 15,683,137 | |||
| Buy | 479,039 | $6.91 | $3.3M | 15,683,034 | |||
| Aslan Fred | Chief Executive Officer | Sell | 27,116 | $9.01 | $244.3K | 1,535,082 −1.7% of holding | |
| Bush Jennifer | COO, CLO, Compliance Officer | Sell | 8,790 | $9.01 | $79.2K | 337,920 −2.5% of holding | |
| Banerjee Subhashis | Chief Medical Officer | Sell | 7,037 | $9.01 | $63.4K | 144,963 −4.6% of holding | |
| Horan Christopher | Chief Tech Operations Officer | Sell | 7,002 | $9.01 | $63.1K | 293,450 −2.3% of holding | |
| Raymon Heather | SVP, Research and Development | Sell | 3,095 | $9.01 | $27.9K | 148,228 −2% of holding | |
| 3 fills | Buy | 7,942,707 | $11.52 | $91.5M | 15,203,995 | ||
| Aslan Fred | President and CEO | Sell 10b5-1 | 3,187 | $6.00 | $19.1K | 1,209,948 −0.3% of holding | |
| Aslan Fred | President and CEO | Sell 10b5-1 | 6,375 | $3.38 | $21.5K | 343,999 −1.8% of holding | |
| Aslan Fred | President and CEO | Sell 10b5-1 | 25,500 | $6.00 | $153.0K | 356,721 −6.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.